Johan Baeck,
VP, Clinical Development & Medical Affairs,
Jounce Therapeutics
Johan is a physician with more than twenty-five years of experience in the pharmaceutical industry as well as over ten years in Oncology clinical development and medical affairs. Focus has been on both targeted agents, small molecules as well as antibody therapies; in this in both solid and liquid tumors. Johan worked for several years at Novartis in Oncology Translational Medicine with particular focus on biomarker driven clinical studies in order to identify the optimal patient population as well as optimize clinical benefit. In addition, Johan has worked closely with other functions while in medical affairs to optimize pre as well as post-launch programs to further optimize business opportunities.
Emergence of ICOS hi CD4 T Cells is Associated with Tumor Reduction, Progression-Free Survival, and Overall Survival in Advanced Cancer Patients Treated with Vopratelimab, an ICOS Agonist
Tuesday, 29 October 2019 at 08:30
Add to Calendar ▼2019-10-29 08:30:002019-10-29 09:30:00Europe/LondonEmergence of ICOS hi CD4 T Cells is Associated with Tumor Reduction, Progression-Free Survival, and Overall Survival in Advanced Cancer Patients Treated with Vopratelimab, an ICOS AgonistImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Vopratelimab is an ICOS agonist antibody intended to stimulate primed CD4 T effector cells. In the ICONIC trial, peripheral T cell phenotyping demonstrated emergence of an ICOShi subset of activated CD4 T effector cells associated with tumor reductions and improved PFS and OS, with expansion of peripheral T cell receptor clones found in the original matched archival tumor. Future development focuses on settings in which ICOShi CD 4 T effector cells are primed to respond to vopratelimab.
Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-10-29 08:30:002019-10-29 09:30:00Europe/LondonEmergence of ICOS hi CD4 T Cells is Associated with Tumor Reduction, Progression-Free Survival, and Overall Survival in Advanced Cancer Patients Treated with Vopratelimab, an ICOS AgonistImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
